FMO5 and chronic granulomatous disease: When NET formation is impaired, as a result of NADPH oxidase or myeloperoxidase (MPO) deficiency (5), an immunodeficiency condition ensues, i.e., in chronic granulomatous disease, due to defective NADPH oxidase, restoration of NET formation by gene therapy allowed the control of severe fungal infection (6).